ANTX

AN2 Therapeutics, Inc.

2.16 USD
-0.01 (-0.46%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AN2 Therapeutics, Inc. stock is down -4.85% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 June’s closed higher than May.

About AN2 Therapeutics, Inc.

AN2 Therapeutics is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.